20 episodes

Physician's Weekly offers in-depth interviews with the most highly respected experts in the medical community, weighing in on landmark research, trending topics, and offering insight on issues affecting everyday medical practice. In collaboration with Medicom Medical Publishers, Physician's Weekly Podcast continues to maintain the company's nearly 40 year reputation as a trusted resource for healthcare professionals.

Physician's Weekly Podcast Physician's Weekly

    • Health & Fitness
    • 5.0 • 2 Ratings

Physician's Weekly offers in-depth interviews with the most highly respected experts in the medical community, weighing in on landmark research, trending topics, and offering insight on issues affecting everyday medical practice. In collaboration with Medicom Medical Publishers, Physician's Weekly Podcast continues to maintain the company's nearly 40 year reputation as a trusted resource for healthcare professionals.

    Phase 3 TULIP Trial, HER2+ Breast Cancer; Deep Dive into Doctor-Patient Privilege; CVD and Psoriatic Disease

    Phase 3 TULIP Trial, HER2+ Breast Cancer; Deep Dive into Doctor-Patient Privilege; CVD and Psoriatic Disease

    Breast cancer is the most common cancer among women, apart from skin cancers. According to the National Breast Cancer Foundation, Inc., about 1 in 8 American women will experience this cancer in their lives. Breast cancer is an incredibly difficult disease to fight or to watch a loved one go through. Raising awareness of the scope and seriousness of this disease is one of the most important and impactful functions of breast cancer events and promotional items. Fundraising events, such as walks and fun runs, have become a common way to raise awareness about this issue and financially support the people and families who have been affected by this disease. Individuals as well as nonprofit organizations like the Susan G. Komen Breast Cancer Foundation and Breastcancer.org have taken it upon themselves to earn money for breast cancer research. One of the slogans often used is, Breast Cancer Awareness Is Not Just a Month.
     Welcome to this episode of Physician’s Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly. We have 3 fantastic in-depth interviews for you this week. 
    Later in this podcast, Physician’s Weekly’s Senior Editor Martta Kelly interviews Dr John Barbieri , Dermatologist at Brigham and Women's Hospital in Boston about cardiovascular risk factors in patients with psoriasis and psoriatic arthritis. We know that patients with psoriasis and psoriatic arthritis have an increased risk of cardiovascular mortality, but are less likely to have traditional cardiovascular risk factors identified and managed. This is a major evidence to practice gap. To improve the prevention of cardiovascular disease in patients with psoriatic disease, Dr Barbiera lays out some pragmatic approaches for physicians. 
    Also in this podcast, we’re back again this week with Physician’s Weekly regular contributor, known by the pseudonym Dr. MedLaw, a board-certified radiologist and medical malpractice attorney. Today she takes a deep dive in the doctor-patient privilege, what that means, when and how it can be used, and why it is important. Did you know that patient privilege came about as a public health intervention to prevent the spread of venereal disease?
    But  firstly, in honor of Breast Cancer Awareness Month, today we will kick off our podcast with an interview with Dr. Marco Timmers, the CEO of up-and-coming pharmaceutical company Byondis, who presented their initial data from the phase 3 TULIP trial in breast cancer patients during the Presidental Symposium at the European Society of Medical Oncology, just a few weeks ago. Their new antibody-conjugate drug, called trastuzumab duocarmazine was compared to the physician’s choice for the 3rd line setting in 436 metastatic HER2-positive breast cancer. The results showed impressive efficacy in the initial topline results. 
    Enjoy listening. 

    • 28 min
    Much-Anticipated Phase 3 DESTINY-Breast03 Trial / Phototherapy for Psoriasis and More!

    Much-Anticipated Phase 3 DESTINY-Breast03 Trial / Phototherapy for Psoriasis and More!

    Welcome to this episode of Physician’s Weekly Podcast,  in collaboration with Physician’s Weekly. We have 3 fantastic in-depth interviews for you this week. 
    The European Society of Medical Oncology ended a few days ago and later in this episode,  I had the opportunity to speak with Dr. Javier Cortes, in Barcelona, Spain about his Presidential Symposium late-breaking presentation held at that meeting, in which he revealed the data from the much-anticipated phase 3 DESTINY-Breast03 trial for patients with advanced breast cancer. The results of the antibody-drug conjugate trastuzumab deruxtecan compared head-to-head with the current standard, called TDM1,  were practice-changing, with spectacular efficacy (I am not sure I have ever seen a P-value with 22 zeros) and excellent safety outcomes.
    Also in this episode, our correspondent Dylan Prentner speaks with pediatrician Umbereen Nehal, who was Chief Medical Officer and Vice President of Medical Affairs for Community Healthcare Network in New York city. In addition, Dr. Nehal led a nationwide campaign as chair of the Task Force of American Muslims for Affordable Health Care that was conducted in conjunction with the White House, where she leveraged community resources to educate and enroll American Muslims in new health coverage options. In recognition of this work, Nehal was honored by an invitation from President Barack Obama to the White House. Dr. Nehal talks with us about how to find the balance of hope and humanism in what she says is a system of perverse incentives.
    But first, Physician’s Weekly speaks with dermatologist Dr Sophie Weatherhead from Newcastle, UK  about their recently published research in phototherapy and psoriasis .
     
    Further reading:
    Watson N, Wilson N, Shmarov F, Zuliani P, Reynolds NJ, Weatherhead SC. The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy. J Eur Acad Dermatol Venereol. 2021 Jul 13. doi: 10.1111/jdv.17519. Epub ahead of print. PMID: 34255884.

    • 37 min
    Awake Prone Positioning Key to COVID; Benefits and Revenue with RPM; Paraspinous Tension Band for Spinal Stenosis

    Awake Prone Positioning Key to COVID; Benefits and Revenue with RPM; Paraspinous Tension Band for Spinal Stenosis

    This podcast is sponsored by Anelto, a leading technology platform that enables innovative healthcare solutions to keep seniors connected to healthcare providers from anywhere. Visit www.anelto.com.

    Welcome to this episode of Physician’s Weekly Podcast. My name is Dr. Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly. We have 3 great in-depth interviews for you this week covering a new trial with promising results to relieve common lower back pain, remote patient monitoring of senior citizens, and a trial showing that having COVID patients position themselves in the prone position, so-called “awake prone positioning”, has improved outcomes in patients with severe COVID-19.     

    Todd Alamin, MD, spinal surgeon at Stanford University: About 140,000 back pain patients are treated with lumbar fusion in the US every year, and we discuss their clinical trial data suggesting that perioperative outcomes are far better using a perispinous tension band after decompression, as opposed to lumbar fusion after decompression, with at least identical, if not better, long term results
    Later in this episode, Physician’s Weekly speaks with Jie Li, PhD, RRT, RRT-ACCS, RRT-NPS from Rush University in Chicago and Professor Stephan Ehrmann, MD, PhD, from the Intensive Care Unit at the University Hospital in Tours, France about their recent study published in the Lancet Respiratory Medicine looking at awake prone positioning in patients with severe COVID-19. In this prospectively designed, multicenter, international, randomized, open-label meta-trial, with a large sample size (1121 patients), these 2 researchers found that awake prone positioning reduced the incidence of treatment failure within 28 days of enrolment (the primary composite outcome of intubation or death) in patients with acute severe hypoxemic respiratory failure due to COVID-19 supported with high-flow nasal cannula.
    Also in this episode, our correspondent Dylan Prentner speaks with Mark Denissen , the President and Chief Executive Officer of Anelto about remote patient monitoring  (RPM) of seniors by real-time symptom tracking. Anelto RemoteCare tracks patient engagement, identifies common requests, questions, and commands; and even tracks user responses and adherence to protocols with alerts and reminders.
    Technologies such as Remote Patient Monitoring are helping transform senior patient care, ensuring patient safety and well-being while ​continuing to live independently. Most ​RPM ​solutions​ ​are not developed specifically with the senior population in mind, especially those with chronic conditions.  ​For seniors, RPM needs to be a complete solution that is easy to use with 24/7 access to care management providers. ​ Visit www.anelto.com.

    Ehrmann S, Li J, et al; Awake Prone Positioning Meta-Trial Group. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021 Aug 20:S2213-2600(21)00356-8. 

    • 31 min
    Anticipated EMPEROR-Preserved Trial for HFpEF; Delta Variant is Gorilla Glue

    Anticipated EMPEROR-Preserved Trial for HFpEF; Delta Variant is Gorilla Glue

    An interview with lead investigator on full results from EMPEROR-Preserved Trial, which affirm that empagliflozin lowers the risk of CVD for heart failure in patients with HFpEF.

    Welcome to this episode of Physician’s Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly.  This week I am recording this episode in the Italian alps, while attending the European Association of Urology Guidelines Panel meeting for Renal cell carcinoma, but we have 2 great in-depth  interviews for you this week.
     
    Later in this episode, Physician’s Weekly’s Editorial Director Chris Cole interviews Dr. J. Stacey Klutts, a medical microbiologist at Rush University, about his op-ed in the Tampa Bay Times comparing the Delta variant of SARS-CoV-2 to Gorilla Glue, which went viral. And yes, the pun was intended. Dr Klutts also tells us about exactly how the vaccine was developed and how the Delta variant is detected in patients. Did you know there are currently 13 subtypes of the Delta variant? 
    But first, we speak with the presenter at the European Society of Cardiology Annual Congress HOTLINE plenary talk, prof. Stefan Anker at the Charité Hospital in Berlin, Germany, about the full results of the EMPEROR-Preserved trial, which affirm that empagliflozin lowers the risk of cardiovascular death/hospitalization for heart failure in patients with heart failure and preserved ejection fraction (HFpEF), leading one expert to say this is “a big day for patients living with HFpEF, a big day for heart failure clinicians.”
    The primary endpoint—a composite of CV death and hospitalization for heart failure—was reduced by a relative 21% in patients treated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor emagliflozin.
    Published simultaneously online in the New England Journal of Medicine, these results represent the first trial to show unequivocal benefit of any drug on major heart failure outcomes in patients with heart failure and a preserved ejection fraction. 

    Anker SD, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Aug 27. 
     

    • 31 min
    Advancements in atopic dermatitis; Successful depositions; Isolation and telementoring;

    Advancements in atopic dermatitis; Successful depositions; Isolation and telementoring;

    Welcome to this episode of Physician’s Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly.  
    At the start of the COVID-19 pandemic, stay-at-home orders and other restrictions drastically affected how people lived and worked, resulting in social isolation and economic instability. Not surprisingly, presented at the American Chemical Society  which was held Aug. 22-26,, researchers show that some people turned to a variety of drugs for relief. Using wastewater analysis, the team  lead by Dr Bikram Subedi identified a spike in consumption of easily abused prescription opioids and anti-anxiety sedatives, while some illicit drug use plummeted, between March and June 2020. Their results showed that consumption of hydrocodone — one of the most abused prescription opioids — spiked by 72% from March to June 2020. The researchers suggest the change was because people had easier access to doctors as they switched to telemedicine appointments. Conversely, the use of illicit stimulants dropped by 16% for methamphetamine and 40% for cocaine. The researchers suggest that travel restrictions limited interstate and international trafficking of these drugs.
     
      These data strongly suggest that there is an unmet need in multidisciplinary telementoring services to reduce opioid use in the outpatient setting.  In this episode, Physician’s Weekly’s Senior Editor Martta Kelly interviews Dr. Thomas Delate, a research scientist at Kaiser Permanente, about his study on the value of telementoring services in educating prescribers about chronic pain management, including opioid prescriptions , recently published in Clinical Journal of Pain. I think you will be surprised by the efficacy of this approach. 
    Also in this episode, we speak with our regular expert contributor with the pseudonym Dr. Medlaw on how physicians how to “knock it out of the park” while giving a deposition in a malpractice case and the key elements in preparing to testify.
    But first, we speak with Dr. Bruce Brod, a Professor of Dermatology at University of Pennsylvania, and spokesperson for the America Association of Dermatology, about developments in the treatment and understanding of one of the most common diseases in humans, eczema or atopic dermatitis, which affects up to 30% of children.
     That’s all the time we have for this week’s podcast. Thanks for listening, I hope you learned something about telementoring for chronic pain relief, about the pathophysiology of atopic dermatitis, and about the best way to go about testifying in a court of law. Stay safe and stay healthy. 
     

    • 28 min
    Best Foot Forward, Malpractice Testimony; Virtual Reality vs Opioids ; Dementia Care

    Best Foot Forward, Malpractice Testimony; Virtual Reality vs Opioids ; Dementia Care

    Welcome to this episode of Physician’s Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly.  
    According to the American Burn Association, burn injuries affect approximately 250,000 children in the United States each year. The pain associated with burn injuries extends beyond the injury itself; there is also significant pain from dressing changes, which can be exacerbated by the anxiety of anticipating this additional pain.
    Although opioids relieve burn injury-related pain, they have serious adverse side effects. Prior studies have investigated alternative approaches to pain reduction in burn injury patients that focus on distraction, such as music, hypnosis, toys, and virtual reality.
     In this episode, Physician’s Weekly’s Senior Editor Martta Kelly interviews Dr. Henry Xiang about his research on the use of smartphone-based virtual reality games during dressing changes in pediatric patients with burn injuries, recently published in JAMA Network Open.
    Also in this episode, we speak with Dr. Benjamin Bensadon, an Associate Professor of geriatric medicine at the University of Florida, about developments in dementia care in our ever-increasing aging population.
    But first, we speak with our regular expert contributor with the pseudonym Dr. Medlaw how physician’s can avoid coming across like a jerk while giving a deposition in a court of law. 


    Xiang H, Shen J, Wheeler KK,  Patterson J, Lever K, Armstrong M, Shi J, Thakkar RK, Groner JI, Noffsinger D, Giles SA, Fabia RB. Efficacy of Smartphone Active and Passive Virtual Reality Distraction vs Standard Care on Burn Pain Among Pediatric Patients: A Randomized Clinical Trial. JAMA Netw Open. 2021 Jun 1;4(6):e2112082. doi: 10.1001/jamanetworkopen.2021.12082. PMID: 34152420; PMCID: PMC8218073.
     

    • 28 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Health & Fitness

You Might Also Like